Compugen (NASDAQ:CGEN) Releases Earnings Results

Compugen (NASDAQ:CGEN) released its quarterly earnings data on Monday. The biotechnology company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.05 by $0.55, FiscalAI reports. The company had revenue of $67.33 million during the quarter, compared to the consensus estimate of $14.30 million. Compugen had a return on equity of 70.13% and a net margin of 48.57%.

Here are the key takeaways from Compugen’s conference call:

• Compugen monetized a small portion of future rilvegostomig royalties to AstraZeneca for a $65 million upfront payment (plus $25M at BLA), retaining the majority of royalties while increasing total remaining AstraZeneca milestones to $195 million and extending expected cash runway into 2029.
• Cash and liquidity at year-end were ~$145.6 million (including the AstraZeneca upfront), driving 2025 revenue and turning reported net results positive for Q4 and the year, though those gains were largely driven by one-time upfront/milestone payments.
• Clinical progress continues on COM-701: MAIA‑ovarian dosing has started with 28 sites now open (U.S., France, Israel), pooled Phase 1 data showed tolerability and durable responses in platinum‑resistant ovarian cancer, and an interim readout is expected in Q1 2027 that could enable a monotherapy path to registration.
• Partnered program GS‑0321 (licensed to Gilead) is in Phase 1 after dosing began in Jan 2025; Gilead has paid $90M to date and Compugen is eligible for up to ~$758M in future milestones plus royalties, with clinical updates to be coordinated with Gilead.
• Leadership and discovery priorities shifted with Eran Ophir named CEO and continued investment in the Unigen AI discovery engine and the early‑stage pipeline, signaling ongoing focus on internal target generation and long‑term program development.

Compugen Price Performance

CGEN stock opened at $2.06 on Wednesday. The firm has a 50-day simple moving average of $1.81 and a two-hundred day simple moving average of $1.66. Compugen has a one year low of $1.13 and a one year high of $2.38.

Hedge Funds Weigh In On Compugen

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC increased its stake in shares of Compugen by 3.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company’s stock valued at $2,229,000 after purchasing an additional 51,565 shares in the last quarter. Jane Street Group LLC lifted its position in shares of Compugen by 1,077.0% in the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock valued at $700,000 after acquiring an additional 359,785 shares in the last quarter. State Street Corp lifted its position in shares of Compugen by 3.9% in the fourth quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock valued at $603,000 after acquiring an additional 14,701 shares in the last quarter. Two Sigma Investments LP boosted its stake in shares of Compugen by 10.6% in the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 18,929 shares during the last quarter. Finally, Marshall Wace LLP increased its position in shares of Compugen by 135.7% during the fourth quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 61,202 shares in the last quarter. 12.22% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CGEN has been the subject of several analyst reports. HC Wainwright began coverage on shares of Compugen in a report on Wednesday, January 7th. They issued a “buy” rating and a $4.00 target price for the company. Wall Street Zen raised Compugen from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $4.00.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.